Nav: Home

PSA, a prostate cancer marker, activates vascular and lymphangiogenic growth factors

May 24, 2019

Together with its partners, a research group led by Docent Michael Jeltsch at the University of Helsinki, Finland, has discovered new mechanisms which activate the vascular endothelial and lymphangiogenic growth factors VEGF-C and VEGF-D. These growth factors play a central role not only in fetal development but in the spread of cancer and the formation of metastases.

Most fatalities caused by cancers that produce tumours - among others, prostate cancer - are specifically the result of metastases. Understanding the chain of events leading to the development of metastases, as well as the related key factors, is necessary for finding means to inhibit or halt the process.

The researchers discovered two new proteolytic enzymes (proteases) which are able to activate both growth factors, VEGF-C and VEGF-D. One of the enzymes is the prostate-specific antigen (PSA), which is also used as a marker for prostate cancer. In addition to the prostate, VEGF-C and PSA occur in semen, where they may have a reproductive impact, particularly on fertility.

The researchers also found that the cathepsin D protease is able to activate VEGF-C and VEGF-D. It was already previously known that cathepsin D is related to the formation of metastases, but detailed information on the mechanism of action has been lacking.

"These new findings provide a great deal of new information on the functioning of lymphangiogenic and vascular endothelial growth factors in general and specifically on their role in prostate cancer and reproductive biology," Jeltsch notes.

"In the future, our discoveries may help in both developing novel cancer drugs as well as identifying and treating mechanisms related to infertility."
-end-


University of Helsinki

Related Prostate Cancer Articles:

ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
Patient prostate tissue used to create unique model of prostate cancer biology
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Moffitt Cancer Center awarded $3.2 million grant to study bone metastasis in prostate cancer
Moffitt researchers David Basanta, Ph.D., and Conor Lynch, Ph.D., have been awarded a U01 grant to investigate prostate cancer metastasis.
New findings concerning hereditary prostate cancer
For the first time ever, researchers have differentiated the risks of developing indolent or aggressive prostate cancer in men with a family history of the disease.
Prostate cancer discovery may make it easier to kill cancer cells
A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy.
New test for prostate cancer significantly improves prostate cancer screening
A study from Karolinska Institutet in Sweden shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
The dilemma of screening for prostate cancer
Primary care providers are put in a difficult position when screening their male patients for prostate cancer -- some guidelines suggest that testing the general population lacks evidence whereas others state that it is appropriate in certain patients.
Risk factors for prostate cancer
New research suggests that age, race and family history are the biggest risk factors for a man to develop prostate cancer, although high blood pressure, high cholesterol, vitamin D deficiency, inflammation of prostate, and vasectomy also add to the risk.
Prostate cancer is 5 different diseases
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
UH Seidman Cancer Center performs first-ever prostate cancer treatment
The radiation oncology team at UH Seidman Cancer Center in Cleveland performed the first-ever prostate cancer treatment April 3 using a newly-approved device -- SpaceOAR which enhances the efficacy of radiation treatment by protecting organs surrounding the prostate.

Related Prostate Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".